Validation of a Mass Spectrometry–Based Proteomics Molecular Pathology Assay
Mass spectrometry-based proteomics has been applied to many fields and has made major contributions to our understanding of biology and medicine. Translation of this technology and assays to patient testing has been limited despite grand expectations. The amyloid protein identification by LC-MS test is one successful example of the adaptation of this technology by molecular and clinical pathology laboratories. Through the illustration of this assay, we will address some of these challenges and outline a process for validation and implementation of mass spectrometry-based proteomics in the molecular pathology laboratory.
Authors
- Maria Stella Ritorto (ORCID: https://orcid.org/0000-0001-9861-6863)
- A. Walland
- Ahmet Doǧan (ORCID: https://orcid.org/0000-0001-6576-5256)
- Jessica Wardrope
- Oana Madalina Mereuta (ORCID: https://orcid.org/0000-0003-3741-3784)
- Jeeyeon Baik
- S. Stephen Yi (ORCID: https://orcid.org/0000-0003-0047-8103)
- Ashley Wooten
- Jessica R. Chapman (ORCID: https://orcid.org/0000-0002-4080-8667)
- Kristel Flor (ORCID: https://orcid.org/0009-0008-6880-604X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Molecular & Cellular Proteomics
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.mcpro.2025.101487
- Primary Topic
- Advanced Proteomics Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Farmer Family Foundation
- National Institutes of Health